noom glp-1 companion program Access and Transparency The Noom Engagement Report: New
Description
Wilkinson, D
1 With patent challenges to branded GLP-1 products advancing across multiple jurisdictions and demand for affordable obesity and diabetes therapies continuing to grow, the generic entry raises practical questions for the broader GLP-1 commercial ecosystem: how It is estimated 589 million adults are currently living with diabetes worldwide a number projected to reach 853 million by 2050 underscoring the scale of the patient population these therapies stand to reach
Stability Testing Absent or Inadequate Establishing shelf life and storage conditions requires an ongoing, documented stability program
The FDA did create a new Genetic Metabolic Diseases Advisory Committee in 2024, which expands its capacity to evaluate exactly this kind of therapy
The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway
